Biotech Values

[DewDiligence]

GTCB (from Yahoo):

>>
Re: GTCB versus Pharming
by: DewDiligence
02/21/06 02:19 pm
Msg: 27608 of 27631

>Pharming is worth 400 m without approval pending.<

European biotech investors have relatively few hometown choices, so Pharming gets a lot more attention than GTCB from the sell-side analysts. This will presumably change if ATryn is approved.

p.s. GTCB investors should know at least a modicum of basic information about Pharming because the two companies could end up as one company in due course.

[Posted as a reply to: Msg 27469 by philippelybaert]
<<